Vallabh Janardhan: Vascular Disease Is Ultimately A Story of Thrombosis
Vallabh Janardhan, Co-Founder and CMO at Insera Therapeutics, Inc., shared on LinkedIn:
”Dallas CV Updates 2026 reinforced something I’ve been thinking about increasingly: vascular disease is ultimately a story of thrombosis.
From coronary plaque rupture to embolic stroke to venous thromboembolism, the final common pathway is clot biology.
A particularly compelling discussion this year centered on Lipoprotein(a) by Dr. Shahzeb Khan — not only as an atherogenic particle, but as a pro-thrombotic contributor that may amplify clot formation across vascular beds.
As our understanding deepens, prevention and intervention are no longer separate conversations.
Credit to Dr. Srini Potluri and Dr. Robert Smith for convening a forum that blends clinical excellence with forward-looking discussion at Baylor Scott and White The Heart Hospital.
Always energizing to engage with colleagues shaping the next phase of cardiovascular care in Dallas and beyond.”
Stay updated with Hemostasis Today.
-
Oct 5, 2026, 13:24Abdul Muqtadir Abbasi: Diagnostic Pearls for Evaluating Isolated Thrombocytopenia in Residents
-
Oct 5, 2026, 13:16Katerina Pavenski: Rethinking What ‘Normal’ Means for Iron Deficiency
-
Oct 5, 2026, 13:09Rick Matthews: Balancing Established VTE Partnerships with Innovative Interventional Technologies
-
Oct 5, 2026, 13:01Nawsherwan Mohammad: Recognizing TTP Before the ADAMTS13 Result Arrives
-
Oct 5, 2026, 12:51Bruno Pougault: The Hidden Challenges Behind Anti Xa Testing
-
Oct 5, 2026, 12:41Syed Huzaifa Khan: Rethinking CTRP12 as a Biomarker for In Stent Restenosis
-
Oct 5, 2026, 12:29Mirvat Alasnag: Creating a Space for Women in Cardiovascular Medicine
-
Oct 5, 2026, 11:59Khaoula Mazouzi: The Potential of Haemoglobin Vesicles as an Oxygen Carrier
-
Oct 5, 2026, 11:56Muhammet Özbilen: What Does New Evidence Tell Us About IV Iron in Pregnancy?